Viatris Inc(VTRS) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 6:40 PM ET (Korea 10/28 07:40)
Full metrics table
| Index | S&P 500 | P/E | - | EPS (ttm) | -0.36 | Insider Own | 2.07% | Shs Outstand | 1.16B | Perf Week | 0.38% |
| Market Cap | 21.50B | Forward P/E | 6.89 | EPS next Y | 7.99% | Insider Trans | -0.21% | Shs Float | 1.12B | Perf Month | 2.46% |
| Enterprise Value | 33.72B | PEG | 0.89 | EPS next Q | 0.64 | Inst Own | 93.07% | Short Float | 3.37% | Perf Quarter | 5.05% |
| Income | -0.41B | P/S | 1.46 | EPS this Y | 7.13% | Inst Trans | -0.2% | Short Ratio | 4.1 | Perf Half Y | 26.32% |
| Sales | 14.75B | P/B | 1.52 | EPS next 5Y | 7.7% | ROA | -1.12% | Short Interest | 37.93M | Perf YTD | 50.36% |
| Book/sh | 12.34 | P/C | 15.25 | EPS past 3/5Y | - -21.93% | ROE | -2.75% | 52W High | -0.16% ($18.75) | Perf Year | 79.65% |
| Cash/sh | 1.23 | P/FCF | 11 | Sales past 3/5Y | -4.04% 3.66% | ROIC | -1.58% | 52W Low | 88.71% ($9.92) | Perf 3Y | 113.45% |
| Dividend Est. | $0.52 (2.77%) | EV/EBITDA | 7.97 | EPS Y/Y TTM | 87.81% | Gross Margin | 39.58% | Volatility(W/M) | 2.26% 2.62% | Perf 5Y | 42.9% |
| Dividend TTM | 0.48 | EV/Sales | 2.29 | Sales Y/Y TTM | 4.92% | Oper. Margin | 9.69% | ATR (14) | 0.48 | Perf 10Y | -50.76% |
| Dividend Ex-Date | 2026/8/21 | Quick Ratio | 0.87 | EPS Q/Q | -2517.95% | Profit Margin | -2.78% | RSI (14) | 62.32 | Recom | 2.21 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.49 | Sales Q/Q | 5.05% | SMA20 | 4.45% ($17.92) | Beta | 0.89 | Target Price | $20.33 |
| Payout | - | Debt/Eq | 0.96 | Earnings | 2026/11/5 | SMA50 | 8.31% ($17.28) | Rel Volume | 0.66 | Prev Close | $18.29 |
| Employees | 30000 | LT Debt/Eq | 0.83 | EPS/Sales Surpr. | 14.79% 2.21% | SMA200 | 18.44% ($15.81) | Avg Volume(3M) | 9.24M | Price | $18.72 |
| IPO | 1980/3/17 | Option/Short | Yes/Yes | Trades | 29768 | Volume | 6,069,893 | Change | 2.35% |
💊 A pharmaceutical company that supplies generics (copy drugs) and specialty pharmaceuticals globally. It holds a broad portfolio of generics, biosimilars, and branded drugs across various therapeutic areas, supplying medicines to markets around the world. It is one of the leading generic and specialty pharmaceutical companies with an extensive product portfolio and global distribution network.
Over the past 1 year, on the higher side
0% below its 1-year high.
Traded less than usual. That is 66% of its average volume.
Next earnings report: November 5
8 days to go.
VTRS keeps an operating profit but posts a net loss
Of every $100 in sales, $9.69 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +7.1% this year.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $146. Peers typically go for $225.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +42.9%. The S&P 500 did +70% over the same period.
Tap to view numbers
Dividends are paid consistently
Pays 2.77% annually in dividends.
Tap to view numbers
Ownership looks stable
Institutions hold 93.1%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #6 of 83 in the industry
Based on market cap of $22B.
FAQ
What kind of company is VTRS?
VTRS belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of VTRS?
The market cap of VTRS is approximately $21.5B, ranking 583 within its sector.
Does VTRS pay dividends?
VTRS has a dividend yield of approximately 2.77%, with an annual dividend of $0.52.
What is the 52-week high and low for VTRS?
VTRS has recorded a 52-week high of $18.75 and a low of $9.92.
